138 related articles for article (PubMed ID: 26485304)
1. Improved Outcomes of Hematopoietic Stem Cell Transplantation in Patients With Infantile Malignant Osteopetrosis Using Fludarabine-Based Conditioning.
Natsheh J; Drozdinsky G; Simanovsky N; Lamdan R; Erlich O; Gorelik N; Or R; Weintraub M; Stepensky P
Pediatr Blood Cancer; 2016 Mar; 63(3):535-40. PubMed ID: 26485304
[TBL] [Abstract][Full Text] [Related]
2. Successful hematopoietic stem cell transplantation for osteopetrosis using reduced intensity conditioning.
Shadur B; Zaidman I; NaserEddin A; Lokshin E; Hussein F; Oron HC; Avni B; Grisariu S; Stepensky P
Pediatr Blood Cancer; 2018 Jun; 65(6):e27010. PubMed ID: 29469225
[TBL] [Abstract][Full Text] [Related]
3. [Allogeneic stem cell transplantation for 8 patients with malignant infantile osteopetrosis in China].
Zhu GH; Qin MQ; Wang B; Zhou X; Yang J; Jia CG; Wu Y; Wang XS; Wu MY
Zhonghua Er Ke Za Zhi; 2012 Nov; 50(11):807-12. PubMed ID: 23302608
[TBL] [Abstract][Full Text] [Related]
4. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
5. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S
Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007
[TBL] [Abstract][Full Text] [Related]
6. Fludarabine-based conditioning chemotherapy for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia.
Al-Zahrani H; Nassar A; Al-Mohareb F; Al-Sharif F; Mohamed S; Al-Anazi K; Patel M; Rasheed W; Saleh AJ; Bakr M; Ahmed S; Ibrahim K; Hussain F; Elkum N; Elhassan T; Nurgat Z; Chaudhri N; Aljurf M
Biol Blood Marrow Transplant; 2011 May; 17(5):717-22. PubMed ID: 20736079
[TBL] [Abstract][Full Text] [Related]
7. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan.
Shimoni A; Hardan I; Shem-Tov N; Rand A; Herscovici C; Yerushalmi R; Nagler A
Leukemia; 2007 Oct; 21(10):2109-16. PubMed ID: 17690701
[TBL] [Abstract][Full Text] [Related]
8. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
9. Non-total body irradiation myeloablative conditioning with intravenous busulfan and cyclophosphamide in hematopoietic stem cell transplantation for malignant infantile osteopetrosis.
Behfar M; Dehghani SS; Hosseini AS; Jalali A; Hamidieh AA; Ghavamzadeh A
Pediatr Transplant; 2015 Jun; 19(4):422-7. PubMed ID: 25879376
[TBL] [Abstract][Full Text] [Related]
10. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W;
J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954
[TBL] [Abstract][Full Text] [Related]
11. Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients.
Lee JW; Kang HJ; Kim S; Lee SH; Yu KS; Kim NH; Jang MK; Kim H; Song SH; Park JD; Park KD; Shin HY; Jang IJ; Ahn HS
Biol Blood Marrow Transplant; 2015 Jan; 21(1):190-5. PubMed ID: 25255163
[TBL] [Abstract][Full Text] [Related]
12. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
[TBL] [Abstract][Full Text] [Related]
13. Engraftment and survival following hematopoietic stem cell transplantation for osteopetrosis using a reduced intensity conditioning regimen.
Tolar J; Bonfim C; Grewal S; Orchard P
Bone Marrow Transplant; 2006 Dec; 38(12):783-7. PubMed ID: 17086207
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH
Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846
[TBL] [Abstract][Full Text] [Related]
15. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity.
Bartelink IH; van Reij EM; Gerhardt CE; van Maarseveen EM; de Wildt A; Versluys B; Lindemans CA; Bierings MB; Boelens JJ
Biol Blood Marrow Transplant; 2014 Mar; 20(3):345-53. PubMed ID: 24315842
[TBL] [Abstract][Full Text] [Related]
17. European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.
Boztug H; Sykora KW; Slatter M; Zecca M; Veys P; Lankester A; Cant A; Skinner R; Wachowiak J; Glogova E; Pötschger U; Peters C
Pediatr Blood Cancer; 2016 Jan; 63(1):139-48. PubMed ID: 26398915
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
[TBL] [Abstract][Full Text] [Related]
19. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
Levine JE; Uberti JP; Ayash L; Reynolds C; Ferrara JL; Silver SM; Braun T; Yanik G; Hutchinson R; Ratanatharathorn V
Biol Blood Marrow Transplant; 2003 Mar; 9(3):189-97. PubMed ID: 12652470
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow transplantation for Fanconi anemia using fludarabine-based conditioning.
Stepensky P; Shapira MY; Balashov D; Trakhtman P; Skorobogatova E; Rheingold L; Brooks R; Revel-Vilk S; Weintraub M; Stein J; Maschan A; Or R; Resnick IB
Biol Blood Marrow Transplant; 2011 Sep; 17(9):1282-8. PubMed ID: 21220033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]